loader2
Partner With Us NRI

Suven Pharmaceuticals Ltd share Price Today

Company details

627.45
637.45
469.45
768.00
6M Return 2.95%
1Y Return 33.28%
Mkt Cap.(Cr) 16,092.33
Volume 107,330
Div Yield 0.95%
OI
-
OI Chg %
-
Volume 107,330

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
CRAMs continue to deliver, outlook stable…
About The Stock

    Dedicated CRAMs supports the global life sciences industry and fine chemical majors in their NCE development endeavours. Its services include custom synthesis, process R&D, scale-up & contract manufacturing.
    • In FY22, CRAMs Pharma vertical contributed 59% of sales. Besides CRAMs Pharma, Suven has also has developed & supplied intermediates/technical for specialty chemicals CRAMs, which accounted for 35% of sales
    • Suven is currently on a three pronged investment plan, 1) relocating R&D centre, 2) replacement and upgradation of blocks at Suryapet facility and 3) additional new block in line with FDA regulations at Pashamylaram facility

Q1FY23

    Strong Q1 numbers driven by strong traction in both Spec Chem and Pharma CRAMs.
    • Sales were up 28% YoY to ₹ 339 crore
    • EBITDA was at ₹ 151 crore, up 32% YoY with margins at 44.5%
    • Consequent PAT was at ₹ 107 crore (up 2% YoY)

Click here for full recommendation

Research view on more stocks

Suven Pharmaceuticals declares Q3FY22 result:

  • The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
  • The Suven Pharma Inc., the WOS of our Company has divested its entire stake (25% amounting to $35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec,2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of $ 41.555 Mn and a stake valued at $15.803 Mn in Raisin Aggregators L.P. Accordingly, Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec'2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Dec'2021.
  • The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totaling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each) for the financial year 2021-22.
  • The Board in its meeting held on 8th February 2022, has given its in-principle approval to evaluate the acquisition opportunity of Caper Pharma Pvt. Ltd., an SEZ unit in Hyderabad engaged in Formulations. The Company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements.
  • The COVID-19 continuous to impact the business and research operations in India and our wholly owned subsidiary, Suven pharma, Inc., USA.

 

 

Result PDF

View Other Company Results

Suven Pharmaceuticals Ltd shares SWOT Analysis

Strengths (4)

  • Company with Low Debt
  • Book Value per share Improving for last 2 years
  • Company with Zero Promoter Pledge

Weakness (9)

  • Promoter holding decreased by more than -2% QoQ
  • Negative profit growth, promoters decreasing shareholding QoQ
  • Inefficient use of shareholder funds - ROE declining in the last 2 years

Opportunity (0)

Data not found

Threats (4)

  • Promoter decreasing their shareholding
  • Companies with growing costs YoY for long term projects
  • High PE (PE > 40)

Resistance and support

R1 637.3
R2 642.4
R3 647.3
Pivot

632.35

S1 627.3
S2 622.4
S3 617.3
EMA SMA
643.5
648.0
645.0
618.5
650.5
644.1
662.6
619.8
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ABU DHABI INVESTMENT AUTHORITY STABLE Bulk Purchase 2024-03-01 698.15 1574000 NSE
AMANSA HOLDINGS PRIVATE LIMITED Bulk Sell 2024-03-01 689.19 3126653 NSE
SOCIETE GENERALE Block Purchase 2024-01-25 685.15 297913 BSE
Name Category Shares
BERHYANDA LIMITED PROMOTER 50.1%

OUR RESEARCH VIEW

Investment recommendation
CRAMs continue to deliver, outlook stable…
Call Date
09 Aug 2022
Entry Price 482.00
Target Price 530.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Suven Pharmaceuticals Ltd Stocks COMPARISON

Financials( in Cr) Suven Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 632.15 1,486.70 1,486.45 4,122.40 1,076.00
% Change 0.30 -0.56 -0.18 0.23 -0.93
Mcap Cr 16,092.33 356,709.13 120,011.07 109,436.94 108,270.78
Revenue TTM Cr 1,330.08 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 432.60 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 43.38 35.64 28.16 79.13 28.08
1 Year Return 33.28 59.59 59.76 21.76 112.04
ROCE 34.28 16.79 14.76 19.30 16.25
ROE 26.46 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,749.38 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 33,796.39 -24,413.80
LAST 3M 102,786.44 -26,675.26
LAST 6M 169,824.52 52,410.32
LAST 12M 262,867.28 126,756.31
NSE Board Meetings Forthcomming

May 27, 2024 l NSE Board Meetings Forthcomming

Suven Pharmaceuticals postpones board meeting

May 22, 2024 l BSE Announcement

Suven Pharmaceuticals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 21, 2024 l NSE Announcement

Date Action Type Ratio
Sep 09, 2022 Dividend 100
Sep 09, 2022 Dividend 500
May 13, 2022 Dividend 100

Suven Pharmaceuticals Ltd Information

Stock PE (TTM)
43.38
Promoter Holding
50.1%
Book Value
76.0279
ROCE
34.28%
ROE
26.46%
Registered Address

8-2-334 SDE Serene Chambers, 3 Floor Avenue 7 Road No 5, Hyderabad, Telangana, 500034

Tel : 91-40-23549414/1142/3311
Email : khrao:suvenpharm.com
Website : http://www.suvenpharm.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 543064
NSE Code : SUVENPHAR
Book Closure Date (Month) : Dec
BSE Group : A
ISIN : INE03QK01018

FAQ’s on Suven Pharmaceuticals Ltd Shares

You can buy Suven Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Suven Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 24, 2024 03:59 PM the closing price of Suven Pharmaceuticals Ltd was Rs.632.15.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 24, 2024 03:59 PM, the market cap of Suven Pharmaceuticals Ltd stood at Rs. 16,092.33.

The latest PE ratio of Suven Pharmaceuticals Ltd as of May 24, 2024 03:59 PM is 43.38

The latest PB ratio of Suven Pharmaceuticals Ltd as of May 24, 2024 03:59 PM is 0.12

The 52-week high of Suven Pharmaceuticals Ltd share price is Rs. 768.00 while the 52-week low is Rs. 469.45

According to analyst recommendations, Suven Pharmaceuticals Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app